DE3525389A1 - Arzneimittel zur behandlung von erkrankungen der gehirngefaesse und altersbedingten cerebralen stoerungen - Google Patents

Arzneimittel zur behandlung von erkrankungen der gehirngefaesse und altersbedingten cerebralen stoerungen

Info

Publication number
DE3525389A1
DE3525389A1 DE19853525389 DE3525389A DE3525389A1 DE 3525389 A1 DE3525389 A1 DE 3525389A1 DE 19853525389 DE19853525389 DE 19853525389 DE 3525389 A DE3525389 A DE 3525389A DE 3525389 A1 DE3525389 A1 DE 3525389A1
Authority
DE
Germany
Prior art keywords
dihydroergocristine
dihydroergocryptine
treatment
age
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19853525389
Other languages
German (de)
English (en)
Inventor
Stefano Mailand/Milano Poli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Poli Industria Chimica SpA
Original Assignee
Poli Industria Chimica SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poli Industria Chimica SpA filed Critical Poli Industria Chimica SpA
Publication of DE3525389A1 publication Critical patent/DE3525389A1/de
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE19853525389 1985-04-04 1985-07-16 Arzneimittel zur behandlung von erkrankungen der gehirngefaesse und altersbedingten cerebralen stoerungen Ceased DE3525389A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT20241/85A IT1200609B (it) 1985-04-04 1985-04-04 Composizione farmaceutice per il trattamento delle turbe cerebrovascolari e del cervello anziano

Publications (1)

Publication Number Publication Date
DE3525389A1 true DE3525389A1 (de) 1986-10-09

Family

ID=11165058

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19853525389 Ceased DE3525389A1 (de) 1985-04-04 1985-07-16 Arzneimittel zur behandlung von erkrankungen der gehirngefaesse und altersbedingten cerebralen stoerungen

Country Status (5)

Country Link
JP (1) JPS61289031A (it)
DE (1) DE3525389A1 (it)
FR (1) FR2579892A1 (it)
GB (1) GB2173401B (it)
IT (1) IT1200609B (it)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08102263A (ja) * 1994-08-05 1996-04-16 Japan Atom Energy Res Inst ジャイロトロン装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2735587A1 (de) * 1977-08-06 1979-02-15 Sandoz Ag Stabile loesungen und verfahren zu deren herstellung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1202885A (en) * 1966-12-22 1970-08-19 Sandoz Ltd Pharmaceutical compositions comprising alkaloids
NO145262C (no) * 1975-05-31 1982-02-17 Sandoz Ag Fremgangsmaate for fremstilling av en stabil loesning av ergotalkaloider eller deres salter
DE2930369A1 (de) * 1979-07-26 1981-02-05 Rentschler Arzneimittel Arzneimittelloesungen
DE3227122A1 (de) * 1982-07-20 1984-01-26 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Stabile loesungen von mutterkornalkaloiden

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2735587A1 (de) * 1977-08-06 1979-02-15 Sandoz Ag Stabile loesungen und verfahren zu deren herstellung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HELWIG, R.: Moderne Arzneimittel, S.894-895, 1980 *

Also Published As

Publication number Publication date
IT8520241A0 (it) 1985-04-04
GB2173401B (en) 1988-10-12
GB8608309D0 (en) 1986-05-08
GB2173401A (en) 1986-10-15
IT1200609B (it) 1989-01-27
FR2579892A1 (it) 1986-10-10
JPS61289031A (ja) 1986-12-19

Similar Documents

Publication Publication Date Title
DE69028542T2 (de) Felbamat zur Behandlung der Lennox-Gastaut syndrome
DE19542281C2 (de) Verwendung von Epinastin für die Behandlung der Migräne
DE3587151T2 (de) Behandlung von gastrointestinalkrankheiten durch anwendung von 5-ht3-antagonisten.
DE69115247T2 (de) Behandlung von fettleibigkeit mit einem alpha-2-adrenergen-agonisten und einem wachstumshormon freigebenden peptid.
DE69001493T2 (de) Verwendung von 5-methyltetrahydrofolsaeure, 5-formyltetrahydrofolsaeure sowie deren pharmazeutisch geeigneten salzen zur herstellung von arzneimitteln mit gesteuerter freigabe zur verwendung in der therapie depressiver stoerungen sowie die auf diese weise hergestellten arzneimittel.
DE60009346T2 (de) Buprenorphin enthaltende analgetische zusammensetzungen
DE3686622T2 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
DE3218761C2 (it)
DE69904922T2 (de) Pharmazeutische zusammensetzung zur behandlung von alkoholabhängigkeit, die opioid antagonisten mit nmda-rezeptorkomplex-modulatoren enthält
DE3590035T1 (de) Diphenhydramin enthaltende, analgetische und anti-inflammatorische Mittel und Verfahren zu ihrer Verwendung
DE2359128C2 (it)
DE60204694T2 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE68911273T2 (de) Benzothiazepine zur Herstellung von Medikamenten zur Milderung von epileptischen Anfällen.
DE10163667B4 (de) Verwendung von Desoxypeganin zur Behandlung der klinischen Depression
DE3525389A1 (de) Arzneimittel zur behandlung von erkrankungen der gehirngefaesse und altersbedingten cerebralen stoerungen
DE2527552A1 (de) Mittel zur behandlung von krankheitszustaenden, die durch demyelierungsprozesse oder hypercholinergie bedingt werden
DE2720194A1 (de) Verwendung von trazodon und etoperidon zum behandeln des parkinson-tremors und anderer extra- pyramidaler syndrome
DE69725613T2 (de) Neue therapeutische verwendung eines thienylcyclohexylaminderivates
DE3525388C2 (it)
DE3419067C2 (it)
DD297557A5 (de) Verwendung von dopamin-autorezeptor-agonisten bei der behandlung von drogenabhaengigkeit
EP1667769A2 (de) Verwendung von galanthamin und seinen derivaten zum herstellen von arzneimitteln
DE3320187A1 (de) Verwendung von n-(diethylaminoethyl)-2-methoxy-5-methylsulfonylbenzamid
EP0398171A2 (de) Verwendung von Imidazodiazepinen bei der Behandlung von neurologischen Symptomen, welche mit zirkulatorischen Störungen des Gehirns assoziiert sind
EP1631282A1 (de) Verwendung des hydrochlorids der wirkstoffbase 1-[n2-[3,5-dibrom- n-[[4-(3,4-dihydro-2(1h)-(oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazin in kombination mit sumatriptan zur behandlung von migräne

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection